4820 Emperor Boulevard
711 articles with IQVIA
IQVIA Launches First Technology-Enabled COVID-19 Trial Matching Solution within the U.S. to Accelerate Treatment and Vaccine Development
IQVIA™, a leader in Human Data Science, announced its new technology-enabled COVID-19 Trial Matching Tool at c19trials.com, which is one of the world’s first online platforms that matches individuals with specific COVID-19 studies to accelerate clinical research projects.
IQVIA Provides Update on Business Conditions in Light of COVID-19 and Provides Revised First-quarter 2020 Guidance; IQVIA will announce first-quarter results and update full-year 2020 guidance on April 28, 2020
IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, updated its first-quarter 2020 guidance and provided a business update in light of the global COVID-19 crisis.
Apttus and HighPoint, an IQVIA Company, Expand Quote-to-Cash System Integrator (SI) Partnership Across the Globe
Apttus and HighPoint, an IQVIA company, Have Partnered To Bring Digital Transformation To Tech Projects Across the Healthcare and Life Sciences Industry
IQVIA Launches Avacare Clinical Research Network to Increase Patients’ Clinical and Research Options
Feb. 20, 2020 13:49 UTC DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--( BUSINESS WIRE )-- IQVIA™ (NYSE: IQV), a leader in human data science, today announced the launch of Avacare Clinical Research Network™, a technology-based global site network that opens opportunities for more clinical trials at experienced clinical and research sites. Avacare’s unique analytical tools help sites in Avacare’s network match patients to clinical trials faster and more effectively. “We b
CIBMTR® Announces Real World Data Effort to Accelerate Breakthroughs that Transform Patient Experiences in Cellular Therapy with IQVIA
The CIBMTR® announced the selection of IQVIA as it seeks to expand the value real world data can bring to patients, through systematic investigation to generate real world evidence.
IQVIA Holdings Inc. announced that it has agreed to purchase an aggregate of 1,000,000 shares of its common stock in a private transaction from certain of its existing stockholders.
Direct access for consumers to track the spread of the flu and colds in the U.S.
IQVIA™ (NYSE: IQV) announced today that its Linguamatics Natural Language Processing (NLP) platform has been selected as the winner in Questex’s 2019 Fierce Innovation Awards — LifeSciences Edition in the Data Analytics/Business Intelligence category.
IQVIA to Announce Fourth-Quarter and Full-Year 2019 Results and Issue 2020 Guidance on February 12, 2020
IQVIA Holdings Inc., will announce its fourth-quarter and full-year 2019 financial results and issue 2020 guidance before the market opens on Wednesday, February 12, 2020.
IQVIA Holdings Inc. has been named to FORTUNE magazine’s “World’s Most Admired Companies” list.
Joe Rymsza, vice president of Pharmacovigilance and Regulatory Technology Solutions for IQVIA, took time out to discuss trends in PV and regulation in the biopharma industry in the coming year.
IQVIA™ announced that AstraZeneca has selected IQVIA Technologies’ Orchestrated Customer Engagement platform to further its digital agenda and establish its “Field of the Future.”
IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, reported financial results for the quarter ended September 30, 2019.
The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
IQVIA OPE is a SaaS patient engagement solution that bridges the gap between life sciences companies and patients
IQVIA Consumer Health announces its unique global technology and analytics suite to support the self-care and wellness industry from product concept to consumer use
IQVIA™ (NYSE:IQV) is proud to announce its collaboration with Friends of Cancer Research in a cross-industry effort to advance acceptance and drive future uses of real world evidence (RWE).
The first Enterprise Quality Management Solution in the industry with expanded capabilities for European Union Medical Device Regulation regulations and compliance
The offer is for approximately 0.51 percent of the common shares outstanding.
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Baird 2019 Global Healthcare Conference in New York, NY on Wednesday, September 4, 2019 at 9:40 a.m. ET.